In a dramatic policy shift, the Trump administration is planning a five-year experiment to allow Medicare and Medicaid to cover GLP-1 weight loss drugs like Ozempic, Wegovy, and Mounjaro—not just for diabetes, but for obesity treatment. The trial, slated to begin in 2026, signals a major reconsideration of prior policies and could reshape access for millions of Americans struggling with obesity.
The initiative would require participating plans to also offer lifestyle support such as diet and exercise coaching. While hailed by some as a “game changer,” others raise alarm over costs, long-term sustainability, and the risk of dependency on high-priced drugs. With up to 100 million Americans potentially eligible, the stakes—and the price tag—are massive.